BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is an innovative biopharmaceutical company that focuses on creating and commercializing immunomodulation therapies for infectious diseases. The company is currently developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. The company’s technology uses a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. For more information, visit the company’s website at www.bionvax.com.